17 3 2005 6 Chinese Bulletin of Life Sciences Vol. 17, No. 3 Jun., 2005 1004-0374(2005)03-0271-07 sirna 510623 sirna(short interference RNA, sirna) 21~23nt RNA mrna sirna RNA RNA R730.59; Q813 A The new therapy method of cancer sirna HU Hai-Yan, ZHANG Yuan* (Institute of Hamatology, Medical College, Jinan University, Guangzhou 510623, China) Abstract: sirna consists of double-stranded RNA of 21~23 nt, which can induce special mrna degradation. The special gene was interfered by posttranscriptional gene silencing. This paper summarizes the situation of sirna used in the therapy of carcinoma. Key words: posttranscriptional gene silencing; RNA interference; sirna; gene therapy DNA sirna ( ) [1] DNA (transcriptional gene silencing TGS); RNA (posttranscriptional gene silencing PTGS) RNA (RNA interference RNAi) PTGS Fire [2] RNA(double strands dsrna) 2004-06-28 No. 021195 (1976 ) (1948 ) *
272 RNAi dsrna mrna RNA PTGS 21~23nt RNA sirna(short interference RNA sirna) [1] DNA sirna sirna [3~5] sirna 3' 2~3nt UU AA CC GG [6] RNA III sirna sirna II RNA III 3~5 T 3' 1~4 U sirna RNAi RNA PTGS mrna RNAi sirna [7] : PCR PCR sirna mrna PCR sirna mrna mrna RNA RNA (RDRP) mrna III Dicer mrna sirna Dicer dsrna sirna RNA (RNA induce silencing complex RISC) sirna mrna mrna 5' sirna mrna [8] sirna nt RNAi [9] AUG 100~200bp 3' sirna RNAi [10] sirna sirna Ambion QIAGEN (www.ambion.com/techlib/ misc/sirna finder.html www.qiagen.com/sirna) (1) mrna AA 21~23nt 75nt (2)G C 50% (3) GGG sirna RNAi (4) BLAST 21~23nt sirna RNA 15 15 sirna( sirna) sirna 29nt DNA (21nt sirna T7 5' 8nt) sirna sirna RNA III RNA DNA RNA sirna sirna RNAi [11] SBMA sirna 1 sirna 20 70
sirna 273 DNA 1.1 DNA CpG [12] CpG [13] CpG DNMT(DNA ) PCNA DNA CpG GSTP1 P16 E- CpG MBD(CpG ) CpG MBD MeCP2 DNA 5m CpG Sin3a HDAC HDACs MBD3 Mi-2NuRD MBD GSTP1 Mi-2NuRD -DNA 85% 30% 90% CpG Bakker [14] MBD2 MeCP2 HeP3 RT-PCR MBD2 MeCP2 sirna MBD2 MeCP2 CpG 1.2 t(8:21)(q22:q22) AML1/MTG8 10%~15% 21 AML1 (RUNX1) 8 MTG8 (ETO CBF 2T1) [15] AML1/ MTG8 MTG8 N-Cor msin3 Smad3 CAAT [16~17] Heidenreich [18] AML1/MTG8 sirna Kasumi-1 SKON 5' Cy3 sirna 16 sirna RT-PCR AML1/MTG8 mrna 50%~80% ( ) 5 AML mrna sirna sirna sirna TGFβ VitD3 CD11b CD14 sirna CD11b 5%~20% CD14 90% AML1/ MTG8 sirna AML1/MTG8 C/EBFα 15~20, 60 90% M-CSF-R 40% CD11b CD14 AML1/ MTG8 sirna (CML) c-abl 9 22 bcr-abl 210kD (p210) p210 CML CML bcr-abl CML bcr-abl p210 (FDA) Gleevec TM (STI 571) bcr-abl ATP bcr/abl Wohlbold [19] Scherr [20] bcr-abl sirna K562 BCR-ABL bcr/abl 2 DNA sirna DNA DNA DNA C (PKC) PKC (PKCδCF) DNA (DNA-PKcs) DNA p53 DNA [21]
274 DNA-PK PKCδCF c-abl PKCδCF DNA sprad1 sprad9 sphusl PKC Rad9 BH3 Bcl-2 Bcl-xL Bcl-2 Yoshida [22] PKCδ sirna 293T PKCδ mrna Rad9 Bcl-2 DNA 50% G 2 sirna PKCδ DNA 53BP1 Rad51 4 (HDAC4) HDAC4 HDAC Kao [23] HDAC4 sirna HDAC4 53BP1 G 2 DNA ATM ATR PKC sirna Collis [24] sirna 90% 1/4-3 Wortmannin DNA-PKcs LY294002 ATR sirna MMS DNA Cdc25A DNA UV/IR Camptothecin Doxorubicin S/G Cdc25A Xiao [25] sirna Chk1 Cdc25A Cdc25A Cdk1/Cdk2 G 2 3 sirna EZH2 EZH2 EZH2 [26] EZH2 Zeste PcG SET EZH2 SET EZH2 pcdna3 ALPL WASF1 RAC3 CA6 SET EZH2 Graff [27] EZH2 sirna RWPE PL3 48 EZH2 mrna 60% 120 80% G 2 /M Gramil [28] DNA 400 Bax -1(Bax inhibitor-1, BI-1) BI-1 PC- 3 LNCaP Du-145 BI-1 sirna BI-1 BI-1 RNAi Bcl-2 BAG-1 Bcl-2 Takahashi [29] sirna Hela ERK1/2 1(MCL1) Bcl-2 Bcl-2 fortilin MCL1 fortilin MCL1 Zhang [30] sirna fortilin MCL1 sirna MCL1 fortilin fortilin MCL1 p53
sirna 275 p53 Shen [31] p53 sirna MCF-7 A549 16(HPV16) E6 E7 Leirdal [32] p53 sirna HepG2C S Trotta [33] BCR/ABL p53 p53 mdm2 bcr/abl + mdm2 La mdm2 mrna 5'UTR La sirna mdm2 La ErbB3 ErbB3 ErbB MAPK (MM) 12% MM IFNα CR IL-6 MM KAS-6/1 DP-6 IFNα IFNα MAP KAS-6/1 ANBL-6 IFNα ErbB3 Walters [34] ErbB3 sirna KAS-6/1 24 Westernblot ErbB3 IFN INFα IL-6 MAPK STAT ErbB3 IFNα MAPK STAT-3 4 sirna 1(TSP1) (VEGF) TSP1 Filleur [35] VEGF sirna VEGF TSP1 VEGF VEGF VEGF Ras-GAP PKC SPK Raf Ras (GEFs) Ras GEFs TCR PKC RasGTP (Ras-GAP) PKC COS Ras- GTP [36] EDG S1P PDGF BFGF TNF SPK S1P RasGEF SPK ERK [37] T24 24 VEGF 20 S1P 2.3 10 Ras-GTP Shu [38] SPK1, 2 sirna T24 SPK1 sirna VEGF T24 Ras- GTP( ) ERK (Westernblot ) SPK2 sirna Mayerle [39] Westernblot 32 p120 Cadherin/Catenin p120 24 7 9 2 (P<0.05) sirna p120 40%
276 Sp100A Sp100A annexina2 annexina2 Sp100A UPAR plasminogen Moller [40] Sp100A sirna psuper CCL-222 plasminogen 45% 65% plasminogen CCL-222 annexina2 5 sirna (MDR) MDR1 p Pgp Pgp Wu [41] MDR1 sirna MCF-7/AdrR MCF-7/BC-19 MCF-7 24 48 RT-PCR MDR1mRNA Westernblot Pgp 65% Peng [42] MDR 3 sirna K562/A02 RT-PCR MDR Pgp MTT K562 sirna IC 50 K562 58.0 1.54% p170 76.0 1.0% 19.6 1.9% K562 70.4% 6 10 RNAi sirna dsrna RNAi DNA sirna sirna sirna mrna sirna [1] Elbashir S M, Harborth J, Lendeckel W, et al. Duplexes of 21- nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001, 411(6836): 494~498 [2] Fire A, Xu S Q, Montgomery M K, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998, 391: 806~810 [3] Brummelkamp T R, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science, 2002, 296: 550~553 [4] Yu J Y, DeRuiter S L, Turner D L. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA, 2002, 99: 6047~6052 [5] Sui G C, Soohoo C, Affar E I B. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA,2002, 99: 5515~5520 [6] Miyagishi M, Taira K. U6 promoter-driven sirnas with four uridine 3 overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol, 2002, 19: 497~500 [7] Rowley P T. RNA interference. N Engl J Med, 2003, 348(6): 564 [8] Pickford A S, Cogoni C. RNA-mediated gene silencing. Cell Mol Life Sci, 2003, 60(5): 871~882 [9] Harborth J, Elbashir S M, Vandenburgh K, et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev, 2003, 13(2): 83~105 [10] Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilising modifications of synthetic sirnas in mammalian cells. Nucleic Acids Res, 2003, 31(11): 2705~2716 [11] Kim V N. RNA interference in functional genomics and medicine. J Korean Med Sci, 2003, 18(3): 309~318 [12] Robertson K D, Jones P A. DNA methylation: past, present and future directions. Carcinogenesis, 2000, 21: 461~467 [13] Esteller M, Corn P G, Baylin S B, et al. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res, 2001, 61: 4689~4692 [14] Bakker J, Lin X H, Nelson W G. Methl-CpG binding domain
sirna 277 protein 2 represses transcription from hypermethylated π- class glutathine S-transferase gene promoters in hepatocallilar carcinoma cells. J Biol Chem, 2002, 277: 22573~22580 [15] Okuda T, Cai Z L, Yang S L, et al. Expression of a knockedin AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood, 1998, 91: 3134~3143 [16] Jakubowia A, Pouponnot C, Berguido F, et al. Inhibition of the transforming growth factor β1signaling pathway by the AML1/ETO leukemia-assosiated fusion protein. J Biol Chem, 2000, 275: 40282~40287 [17] Pabst T, Mueller B U, Harakawa N, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPα in t(8; 21)myeloid leukemia. Nat Med, 2001, 7: 444~451 [18] Heidenreich O, Krauter J, Riehle H, et al. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8; 21)-positive leukemia cells. Blood, 2003, 101: 3157~3163 [19] Wohlbold L, van der Kuip H, Miething C, et al. Inhibition of bcr/abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood, 2003, 102(6): 2236~2239 [20] Scherr M, Battmer K, Winkler T, et al. Specific inhibition of bcr/abl gene expression by small interfering RNA. Blood, 2003, 101(4): 1566~1569 [21] Blass M, Kronfeld I, Kazimirsky G, et al. Tyrosine phosphorylation of protein kinase Cδ is essential for its apoptotic effect in response to etoposide. Mol Cell Biol, 2002, 22: 182~195 [22] Yoshida K, Wang H G, Miki Y, et al. Protein kinase Cδ is responsible for constitutive and DNA damage-induced phosphorylation of Rad9. EMBO J, 2003, 22: 1431~1441 [23] Kao G D, Mckenna W G, Guenther M G, et al. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol, 2003, 160 (7): 1017~1027 [24] Collis S J, Swartz M J, Nelson W G, et al. Enhanced radiation and chemotherapy- mediated cell killing of human cancer cells by small inhibitiory RNA silencing of DNA repair factors. Cancer Res, 2003, 63(7): 1550~1554 [25] Xiao Z Chen Z, Gunasekera A H, et al. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem, 2003, 278(24): 21767~21773 [26] Dhanasekaran S M. Delineation of prognostic biomarkers in prostate cancer. Nature, 2001, 412: 822~826 [27] Graff J, Konicek B, Lynch R, et al. Eukaryotic translation initiation factor elf-4e is consistently upregulated with human prostate cancer progression: inhibition by sirna or ASO therapy suppresses CaP xenograft growth. Eur J Cancer,2004, 2(8): 17~18 [28] Gramil M, Thelen P, Hemmerlein B, et al. Bax inhibitior-1 is overexpressed in prostate cancer and its specific downregulation by RNA interference leads to cell death in human prostate carcinoma cells. Am J Pathol, 2003, 163(2): 543~552 [29] Takahashi N, Yanagihara M, Ogawa Y, et al. Down-regulation of Bcl-2-interacting protein BAG-1 confers resistance to anti-cancer drugs. Biochem Biophys Res Commun, 2003, 301 (3): 798~803 [30] Zhang D, Li F, Weidner D, et al. Physical and functional interaction between myeloid cell leukemia 1 protein (MCL1) and fortilin. The potential role of MCL1 as a fortilin chaperone. J Biol Chem, 2002, 277(40): 37430~37438 [31] Shen C, Buck A K, Liu X, et al. Gene silencing by adenovirusdelivered sirna. FEBS Lett, 2003, 539(27): 111~114 [32] Leirdal M, Sioud M. Gene silencing in mammalian cells by preformed small RNA duplexes. Biochem Biophy Res Commun, 2002, 295(19): 744~748 [33] Trotta R, Vignudelli T, Candini O, et al. BCR/ABL activates mdm2 mrna translation via the La antigen. Cancer Cell, 2003, 3(2): 145~160 [34] Walters D K, French J D, Arendt B K, et al. Atypical expression of ErbB3 in myeloma cells : cross-talk between ErbB3 and interferon-α signaling complex. Oncogene, 2003, 22: 3598~3607 [35] Filleur S, Courtin A, Ait-Si-Ali S, et al. sirna-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res, 2003, 63(14): 3919~3922 [36] Marais R, Light Y, Mason C, et al. Requirement of Ras-GTP- Raf complexes for activation of Raf-1 by protein kinase C. Science, 1998, 280: 109~112 [37] Spiegel S. Sphingosine 1-phosphate : a ligand for the EDG- 1 family of G-protein-coupled receptor. Ann N Y Acad Sci, 2000, 905: 54~60 [38] Shu X, Wu W C, Mosteller R D, et al. Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. Mol Cell Biol, 2002, 22: 7758~7768 [39] Mayerle J, Friess H, Buchler M W, et al. Up-regulation, nuclear import, and tumor growth stimulation of the adhesion protein p120 in pancreatic cancer. Gastroenterology, 2003, 124(4): 949~960 [40] Moller A, Sirma H, Hofmann T G, et al. Sp100A is important for the stimulatory effect of homeodomain-interacting protein kinase-2 on p53-dependent gene expression. Oncogene, 2003, 22(54):8731~8737 [41] Wu H, Hait W N, Yang J M. Small interfering RNA-induced suppression of MDR1(P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res, 2003, 63: 1515~1519 [42] Peng Z, Xiao Z J, Wang Y, et al. Reversal of multi-drug resistance in K562/A02 cells by small interference RNA of mdr1 gene. Chin J Hematol, 2004, 25(1): 5~7